Share Facebook Twitter LinkedIn Pinterest Email Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so. Source link #Moderna #FDA #change #mind #review #flu #vaccine #concessions change concessions FDA flu Mind Moderna Public News Review vaccine World News